Dapoxetine Hcl
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB04884 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 23 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | migraine disorder | KG + DL |
| 2 | dysthymic disorder | KG + DL |
| 3 | migraine with brainstem aura | KG + DL |
| 4 | migraine with or without aura, susceptibility to | KG + DL |
| 5 | neurotic disorder | KG + DL |
| 6 | atrophoderma vermiculata | KG + DL |
| 7 | ulerythema ophryogenesis | KG + DL |
| 8 | neurotic depression | KG + DL |
| 9 | melancholia | KG + DL |
| 10 | congenital isolated adrenocorticotropic hormone deficiency (disease) | KG + DL |
| 11 | Keppen-Lubinsky syndrome | KG + DL |
| 12 | anxiety disorder | KG + DL |
| 13 | vitamin B12-responsive methylmalonic acidemia | KG + DL |
| 14 | autosomal dominant slowed nerve conduction velocity | KG + DL |
| 15 | agoraphobia | KG + DL |
| 16 | Ohdo syndrome and variants | KG + DL |
| 17 | endogenous depression | KG + DL |
| 18 | benign paroxysmal torticollis of infancy | KG + DL |
| 19 | blepharophimosis - intellectual disability syndrome, Ohdo type | KG + DL |
| 20 | pulmonary hypertension | KG + DL |
| 21 | sciatic neuropathy | KG + DL |
| 22 | kyphoscoliotic heart disease | KG + DL |
| 23 | anxiety | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.